Clinical Trial

Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B

Study acronym: ELIMINATE-B
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and antiviral activity of PBGENE-HBV in adult participants with chronic hepatitis B.
Protocol Amendment History 3 changes
notable Trial sites expanded: 4 -> 7 locations 2026-08-15
notable Primary completion pushed: 2025-12 -> 2026-12 2026-08-15
minor Completion pushed: 2026-12 -> 2027-06 2026-08-15
Trial Details
NCT Number NCT06680232
Lead Sponsor Precision BioSciences, Inc.
Conditions HEPATITIS B CHRONIC
Enrollment 45 participants
Start Date 2024-11-14
Primary Completion 2026-12 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-14